verapamil has been researched along with Liver Failure in 3 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Liver Failure: Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the pharmacokinetic changes of verapamil and its major metabolite, norverapamil, after oral administration of verapamil (10 mg/kg) in rabbits with slight, moderate and severe hepatic failure induced by carbon tetrachloride." | 7.73 | Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. ( Burm, JP; Choi, JS, 2005) |
| "After 21 days of rosiglitazone therapy, hepatic failure developed." | 7.70 | Hepatic failure in a patient taking rosiglitazone. ( Diamond, RH; Forman, LM; Simmons, DA, 2000) |
| "It is indicated for the treatment of hypertension in patients who require more than one agent to achieve blood pressure (BP) targets." | 6.43 | Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. ( Keam, SJ; Reynolds, NA; Wagstaff, AJ, 2005) |
| "The aim of this study was to investigate the pharmacokinetic changes of verapamil and its major metabolite, norverapamil, after oral administration of verapamil (10 mg/kg) in rabbits with slight, moderate and severe hepatic failure induced by carbon tetrachloride." | 3.73 | Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. ( Burm, JP; Choi, JS, 2005) |
| "After 21 days of rosiglitazone therapy, hepatic failure developed." | 3.70 | Hepatic failure in a patient taking rosiglitazone. ( Diamond, RH; Forman, LM; Simmons, DA, 2000) |
| "It is indicated for the treatment of hypertension in patients who require more than one agent to achieve blood pressure (BP) targets." | 2.43 | Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. ( Keam, SJ; Reynolds, NA; Wagstaff, AJ, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, JS | 1 |
| Burm, JP | 1 |
| Reynolds, NA | 1 |
| Wagstaff, AJ | 1 |
| Keam, SJ | 1 |
| Forman, LM | 1 |
| Simmons, DA | 1 |
| Diamond, RH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for verapamil and Liver Failure
| Article | Year |
|---|---|
Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug C | 2005 |
2 other studies available for verapamil and Liver Failure
| Article | Year |
|---|---|
Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride.
Topics: Administration, Oral; Animals; Biological Availability; Calcium Channel Blockers; Carbon Tetrachlori | 2005 |
Hepatic failure in a patient taking rosiglitazone.
Topics: Aged; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Hum | 2000 |